Showing 2461-2470 of 3223 results for "".
- Glaukos to Showcase Technologies at 2024 AAO Annual Meeting in Chicagohttps://modernod.com/news/glaukos-to-showcase-technologies-at-2024-aao-annual-meeting-in-chicago/2482483/Glaukos announced that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, October 18-21, 2024, in Chicago. Glaukos is also sponsoring an educational symposium in conjunction with EyeWorld and AAO entitl
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- Zeiss Launches Micor 700 Lens Extraction Devicehttps://modernod.com/news/zeiss-launches-micor-700-lens-extraction-device/2482459/Zeiss announced the US launch of the Micor 700 lens extraction device, which is designed to eliminate the need for ultrasound, offering a more sustainable and cost-effective solution while expanding the intraocular working space for surgeons. The Micor 700 will debut
- Lumibird Unveils Omnicad Imaging Platform for Ocular Surface Diseasehttps://modernod.com/news/lumibird-unveils-omnicad-imaging-platform-for-ocular-surface-disease/2482453/Lumibird Medical announced the launch of the Omnicad, an imaging platform equipped with integrated AI algorithms designed to aid in the diagnosis of ocular surface disease (OSD). The device, exclusively available in the US market, aims to address the needs of optometrists and ophthalmol
- Hilco Vision Appoints Girisha Chandraraj as CEOhttps://modernod.com/news/hilco-vision-appoints-girisha-chandraraj-as-new-ceo/2482435/Hilco Vision has named Girisha Chandraraj as its new Chief Executive Officer, succeeding Ross Brownlee. Mr. Chandraraj’s has held previous roles as CEO at 'Marbles: The Brain Store' and Elite Sportswear. Most recently, he served as CEO of Careismatic Brands, wher
- Ocuphire Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopiahttps://modernod.com/news/ocuphire-initiates-vega-3-phase-3-trial-evaluating-phentolamine-ophthalmic-solution-075-for-presbyopia/2482432/Ocuphire Pharma announced the first dosing of participants in its VEGA-3 phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia. Ocuphire’s phentolamine ophthalmic solution 0.75% is being developed as a potential alternative t
- Aurion Biotech to Present at ESCRS and Ophthalmology Futures European Forumhttps://modernod.com/news/aurion-biotech-to-present-at-escrs-and-ophthalmology-futures-european-forum/2482430/Aurion Biotech announced its upcoming participation in the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), September 6-10, 2024, in Barcelona. The company will showcase clinical data on its allogeneic cell therapy drug candidate, AURN001. Aurion w
- BlueRock Receives FDA Clearance for IND Application of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-receives-fda-clearance-for-ind-application-of-opct-001-for-primary-photoreceptor-diseases/2482422/Bayer subsidiary BlueRock Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to in
- Oculus Debuts Dual Testing Functionality on Easyfield VR for Enhanced Visual Field Assessmenthttps://modernod.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/Oculus has announced the debut of dual testing functionality on its Oculus Easyfield VR, which allows for both Frequency Doubling Perimetry (FDP) and Standard Automated Perimetry (SAP). The integration of Frequency Doubling Perimetry into the Easyfield VR allows for the potent
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and